CLINICAL EFFICACY AND SAFETY OF MELOXICAM IN A THERAPEUTIC PRACTICE


如何引用文章

全文:

详细

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most common drugs that have analgesic, anti-inflammatory and antipyretic activities. NSAID meloxicam, cyclooxygenase-2 inhibitor, has a favorable pharmacokinetic profile allowing its administration 1 time per day, cumulative effect and ability to accumulation in the joint cavity. According to data from randomized trials, meloxicam demonstrates high efficacy in patients with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and is characterized by well tolerability and high safety.

作者简介

Raisa Stryuk

R Stryuk

参考

  1. Насонов Е.Л., Лазебник Л.Б., Беленков Ю.Н., и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации, М., 2006. C. 88.
  2. Parfitt J, Driman D. Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol 2007;38:527-36.
  3. Насонов Е.Л. Специфические ингибиторы ЦОГ-2: решенные и нерешенные проблемы // Клин. фармакология и терапия 2000. № 1. C. 57-64.
  4. FitzGerald GA, Patrono C. The Coxibs, selective inhibitors of cyclooxygenase-2. New Engl J Med 2001;345:433-42.
  5. Насонов Е.Л. Применение нестероидных противовоспалительных препаратов в медицине в начале XXI в. // РМЖ. 2003. № 11 (7). C. 375-78.
  6. Конорев М.Р., Ковалева Л.Ф. Гастропатия, индуцированная нестероидными противовоспалительными препаратами: факторы риска, лечение, профилактика. 2006. С. 24-25.
  7. Исаков В.А. Гастропатия, связанная с приемом нестероидных противовоспалительных препаратов: патогенез, лечение, профилактика // Клиническая фармакология и терапия. 2005. № 14(2).
  8. Rostom A, Dube C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review. Ann Intern Med 2007;146:376-89.
  9. Цветкова E.C. Оценка эффективности применения мовалиса при остеоартрозе и ревматоидном артрите (данные многоцентрового российского исследования) // Научно-практическая ревматология. 2005. № 2. C. 29-31.
  10. Hawkey CJ, Lanas AI. Doubt and certainty about non-steroidal anti-inflammatory drug in the year 2000: a multidisciplinary expert statement. Am J Med 2001;8(110):79-100.
  11. Hosie J, Distel M, Bluhmki E. Meloхicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br J Rheumatol 1996;35:39-43.
  12. Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability on the selective cyclooхygenase (COХ)-2 inhibitor meloхicam, compared with piroхicam: results of the Safety and Efficacy Large scale Evalution of COХ inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998;37:946-51.
  13. Ding C. Do NSAID affect the progression of osteoarthritis? Inflammation 2002;26:139-42.
  14. Huskinsson EC, Berry P, Gishen P. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. J Rheumatol 1995;22:1941-46.
  15. HenrotinY, Reginster T. In vitro difference among nonasteroidal antiinflammatory drug in their activities related to osteoarthritis pathophysiology. Osteoarthritis Cartilage 1999;7:355-57.
  16. Blot L, Marcelis A, Devogelaer JP, et al. Effects of diclofenac, aceclofenac and meloхicam of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol 2000;131:1413-21.
  17. Иониченок Н.Г., Цветкова Е.С., Карусинов П.С. и др. Влияние современной терапии на прогрессирование остеоартроза коленных суставов // Научно-практическая ревматология. 2005.
  18. Lemmel EM, Bolten W, Burgos-Vargas R, et al. Efficacy and safety of meloхicam in patients with rheumatoid arthritis. J Rheumatol 1997;24:282-90.
  19. Huskinsson EC, Ghozlan R, Kurthen R, et al. A long-term study to evaluate the safety and efficacy of meloхicam therapy in patients with rheumatoid arthritis. Br J Rheumatol 1996;35(1):29-34.
  20. Wojtulewsky JA, Schattenkirchner M, Barselo P, et al. A siх-month double-blend trial to compare the efficacy and safety of meloхicam 7.5 and naproхen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996;35:22-28.
  21. Dougados M, Guerguen A, Nakasche JP, et al. Ankylosing spondylitis: what is the optimum duration of the clinical study ? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oхford) 1999;38:235-44.
  22. Engelhardt G, Homma D, Schlegel K, et al. Anti-inflammatory, analgesic, antipyretic and related properties of meloхicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995;44:423-33.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##